Interv Akut Kardiol. 2024;23(2-3):61-63

Many faces of betablockers

Jan F. Vojáček
1. interní kardioangiologická klinika LF UK a FN Hradec Králové Kardiologie Na Bulovce, s. r. o., Praha

Published: December 12, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vojáček JF. Many faces of betablockers. Interv Akut Kardiol. 2024;23(2-3):61-63.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 40 CZK (1.7 EUR)
    will be unlocked 12.12.2025

    References

    1. https://www.medscape.com/viewarticle/tyranny-beta-blockers-2024a1000apc?&icd=login_success_email_match_fpf.
    2. Bruthans J, Berger J, ©oltés J, et al. Using the national electronic prescription system to determine the primary non-adherence to medication in the Czech Republic. Front Pharmacol. 2023 Mar 22;14:1128457. doi: 10.3389/fphar.2023.1128457. PMID: 37033608; PMCID: PMC10073447. Go to original source... Go to PubMed...
    3. Řiháček I, Souček M, Fráňa P. Betablokátory v léčbě kardiovaskulárních onemocnění. Med. Pro Praxi. 2005;2:58-61. doi: 10.nnnn/med.2005.014.
    4. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol: a multi-centre international study. Br Med J. 1975;3:735-40. Go to original source... Go to PubMed...
    5. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-7. Go to original source... Go to PubMed...
    6. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Málek I, Nyberg G, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet. 1981;2:823-7. Go to original source... Go to PubMed...
    7. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982 Mar 26;247(12):1707-14 doi: 10.1001/jama.1982.03320370021023. Go to original source... Go to PubMed...
    8. Krąiak M. Zkrácený text přednáąky v Kurzu farmaceutické medicíny 25.3.2006. Sborník časopisu Farmakoterapie, 1. díl, říjen 2006, str. 7-12.
    9. Harris AS, Estandia A, Tillotson RF. Ventricular ectopic rhythms and ventricular fibrillation following cardiac sympathectomy and coronary occlusion. Am J Physiol. 1951 Jun;165(3):505-12. doi: 10.1152/ajplegacy.1951.165.3.505. PMID: 14846969. Go to original source... Go to PubMed...
    10. Vrána M, Blazek Z, Fejfar Z, Netusil M, Trcka V. Prevention of ventricular fibrillation in experimental myocardial infarction. Cor Vasa. 1977;19(3):243-5. PMID: 923260.
    11. Vrána M, Fejfar Z, Netu'sil M, Blazek Z, Trcka V. Stimulation threshold studies and the effect of antiarrhythmic drugs. Basic Res Cardiol. 1978 Nov-Dec;73(6):618-26. doi: 10.1007/BF01906799. PMID: 34384. Go to original source... Go to PubMed...
    12. Waagstein F, Rutherford JD. The Evolution of the Use of β-Blockers to Treat Heart Failure: A Conversation With Finn Waagstein, MD. Circulation. 2017 Sep 5;136(10):889-893. doi: 10.1161/CIRCULATIONAHA.117.029934. PMID: 28874420. Go to original source... Go to PubMed...
    13. Leung KL, Fong W, Freedman B, et al. Association between beta-blocker use and obesity in Hong Kong Chinese elders: a post-hoc analysis. Hong Kong Med J. 2020 Feb;26(1):27-34. doi: 10.12809/hkmj198077. Epub 2020 Jan 22. Erratum in: Hong Kong Med J. 2020 Apr 17;26(2):155. doi: 10.12809/hkmj198077-c. PMID: 32051330. Go to original source... Go to PubMed...
    14. Coats AJS. Beta-blockers, hypertension, and weight gain: the farmer, the chicken, and the egg. Hong Kong Med J. 2020 Feb;26(1):6-7. doi: 10.12809/hkmj205093. PMID: 32077860. Go to original source... Go to PubMed...
    15. Sharma AM, Pischon T, Hardt S, et al. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension. 2001 Feb;37(2):250-4. doi: 10.1161/01.hyp.37.2.250. PMID: 11230280 Review. Go to original source... Go to PubMed...
    16. Boxall BW, Clark AL. Beta-blockers and weight change in patients with chronic heart failure. J Card Fail. 2012 Mar;18(3):233-7. doi: 10.1016/j.cardfail.2011.10.016. Epub 2011 Dec 3. PMID: 22385944 Go to original source... Go to PubMed...
    17. Pischon T, Sharma AM. Use of beta-blockers in obesity hypertension: potential role of weight gain. Obes Rev. 2001 Nov;2(4):275-80. doi: 10.1046/j.1467-789x.2001.00044.x. PMID: 12119998 Review. Go to original source... Go to PubMed...
    18. Anekwe CV, Ahn YJ, Bajaj SS, et al. Pharmacotherapy causing weight gain and metabolic alteration in those with obesity and obesity-related conditions: A review., Ann N Y Acad Sci. 2024 Mar;1533(1):145-155. doi: 10.1111/nyas.15112. Epub 2024 Feb 22. PMID: 38385953 Review. Go to original source... Go to PubMed...
    19. DiNicolantonio JJ, Fares H, Niazi AK, et al. beta-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart. 2015 Mar 21;2(1):e000230. doi: 10.1136/openhrt-2014-000230. eCollection 2015. PMID: 25821584 Free PMC article. Review. Go to original source... Go to PubMed...
    20. Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf. 2015 Dec;38(12):1153-68. doi: 10.1007/s40264-015-0339-z. PMID: 26370106. Go to original source... Go to PubMed...
    21. DiNicolantonio JJ, Fares H, Niazi AK, et al. Open Heart 2015;2:e000230. doi:10.1136/openhrt-2014-000230. Go to original source... Go to PubMed...
    22. Palau P, de la Espriella R, Seller J, et al. β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2024 Apr 1;9(4):392-396. doi: 10.1001/jamacardio.2023.5500. PMID: 38324280; PMCID: PMC10851133. Go to original source... Go to PubMed...
    23. Bangalore S, Makani H, Radford M et al. Clinical outcomes with β -blockers for myocardial infarction: a metanalysis od randomized trials. Am J Med. 2014;127:939-95. Go to original source... Go to PubMed...
    24. Vítovec J, ©pinar J, ©pinarová L. Betablokátory po infarktu myokardu a u chronické ICHS. Vnitř Lék. 2022;68(3):178-180. Go to original source...
    25. Yndigegn T, Lindahl B, Mars K, et al; REDUCE-AMI Investigators. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024 Apr 18;390(15):1372-1381. doi: 10.1056/NEJMoa2401479. Epub 2024 Apr 7. PMID: 38587241. Go to original source... Go to PubMed...
    26. Silvain J, Cayla G, Ferrari E, et al; ABYSS Investigators of the ACTION Study Group. Beta-Blocker Interruption or Continuation after Myocardial Infarction. N Engl J Med. 2024 Oct 10;391(14):1277-1286. doi: 10.1056/NEJMoa2404204. Epub 2024 Aug 30. PMID: 39213187. Go to original source... Go to PubMed...
    27. O´Donoghue ML, Montalescot G. What Now For Beta-Blockers Post-Mi? Reconciling REDUCE-AMI and ABYSS. Medscape September 04, 2024. https://www.medscape.com/viewarticle/what-now-beta-blockers-post-mi-reconciling-reduce-ami-and-2024a1000fz1?form=fpf.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.